Skip to main content
. Author manuscript; available in PMC: 2017 Apr 1.
Published in final edited form as: Nanomedicine. 2015 Dec 2;12(3):759–770. doi: 10.1016/j.nano.2015.11.007

Figure 1. Recombinant PR8/RSV HA-F viruses show reactivity to palivizumab.

Figure 1

(A) Inserted sequences in the plasmids PR8/RSV HA-F258-275, PR8/RSV HA-F262-276, and PR8/RSV HA-F262-273. pHW194-HA-derived plasmids PR8/RSV HA-F258-275, PR8/RSV HA-F262-276, and PR8/RSV HA-F262-273 contains the amino acid (aa) sequence of the antigenic site II of the RSV F protein. The aa sequences forming the loop of site Sa of the mutated HA gene are shown. These plasmids contain 18- or 15- or 12-aa insertion in the HA gene between positions 171 and 172, as indicated by the black box, respectively. The inserted aa sequences are indicated by the red color. (B) Palivizumab reactivity. The presence and contents of RSV neutralizing epitopes in the chimeric recombinant viruses PR8 WT, PR8/RSV HA-F258-275, PR8/RSV HA-F262-276, and PR8/RSV HA-F262-273 were determined by ELISA using F protein monoclonal antibody (palivizumab). (C) In vitro growth kinetics. Eggs were infected at 15 EID50 (50% egg infective dose) of PR8 WT, PR8/RSV HA-F258-275, PR8/RSV HA-F262-276, and PR8/RSV HA-F262-273 virus. Samples were collected at 0, 12, 24, 36, and 48 h postinfection. The viral titer in the samples was determined by an egg infection assay.